<DOC>
	<DOCNO>NCT02096042</DOCNO>
	<brief_summary>This clinical research study make 3 phase : Pilot Phase , Phase 1 , Phase 2 . The goal Pilot Phase learn safe give study drug brentuximab vedotin patient AML . The goal Phase 1 learn safety combination brentuximab vedotin azacytidine . The goal Phase 2 learn combination brentuximab vedotin azacytidine help control AML .</brief_summary>
	<brief_title>Phase I/II - Brentuximab/5-Azacytidine Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Study Groups : If find eligible take part study , assign study group base join study . Up 3 group 3-6 participant enrol Pilot Phase , 3 group 3-6 participant enrol Phase I study , 25 participant enrol Phase II . If enrol Pilot Phase , dose brentuximab vedotin receive depend join study . The first group participant receive high dose level brentuximab vedotin . If intolerable side effect see , 2 group enrol receive low dose brentuximab vedotin group . If intolerable side effect see , next phase study begin . If enrolled Phase I , dose brentuximab vedotin receive depend join study . The first group participant receive low dose level brentuximab vedotin high one tolerate Pilot Phase , also receive azacitidine . If intolerable side effect see , 2 group enrol receive low dose brentuximab vedotin group . If intolerable side effect see , next phase study begin . If enrolled Phase 2 , receive brentuximab vedotin high dose tolerate Phase 1 . All participant Phases 1 2 receive dose level azacytidine . Study Drug Administration : If find eligible take part study , receive brentuximab vedotin vein 30 minute Days 1 , 8 , 15 28-day study cycle . If disease appear get good , cycle 4 , dose schedule brentuximab vedotin may change monthly rather weekly dos . If Phase 1 Phase 2 , also receive azacytidine vein injection skin Days 1-7 cycle . You may give standard drug help decrease risk side effect . You may ask study staff information drug give risk . Study Visits : On Day 1 cycle : - You physical exam . - Blood ( 2-3 tablespoon ) draw routine test . - You EKG . - Every 3 Cycles ( Cycles 3 , 6 , 9 , ) , become pregnant , blood ( 1 teaspoon ) urine collect pregnancy test . On Days 8 22 Cycle 1 , blood ( 2-3 tablespoon ) draw routine test . On Day 15 Cycle 1 : - You physical exam . - Blood ( 2-3 tablespoon ) draw routine test . On Day 28 Cycle 1 , Day 1 every 2 cycle ( Cycles 3 , 5 , 7 , ) , bone marrow biopsy and/or aspirate check status disease . After point disease appear get good , do every 3-4 cycle , whenever doctor think need . Length Treatment : You may receive study drug 12 cycle . You longer able receive study drug ( ) disease get bad , intolerable side effect occur , unable follow study direction . Your participation study end-of-study visit . End-of-Study Visit : About 28 day last dose study drug , end-of-study visit : - You physical exam . - Blood ( 2-3 tablespoon ) draw routine test . - You EKG check heart function . - You may bone marrow biopsy and/or aspirate check status disease . - If become pregnant , blood ( 1 teaspoon ) urine collect pregnancy test . If End-of-Study Visit occur within 21 day last dose , call member study team 30-37 day last dose study drug . You ask feel side effect may . This call last 5 minute . This investigational study . Brentuximab vedotin FDA approve commercially available treatment certain type lymphoma previous treatment fail . Its use combination azacitidine investigational . Azacytidine FDA approve commercially available treatment myelodysplastic syndrome ( MDS ) chronic myelomonocytic leukemia ( CMML ) . The study doctor explain study drug ( ) design work . Up 61 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically cytologically confirm AML , acute promyelocytic leukemia , define 2008 World Health Organization ( WHO ) criterion relapse refractory standard chemotherapy . Note : Newlydiagnosed AML patient 60 year old candidate refuse standard chemotherapy also eligible trial . 2 . AML blast must express CD30 ( &gt; /=10 % expression assess flowcytometry 2+ expression immunohistochemistry ) ( whenever possible CD30 expression assess method ) 3 . Age 18 year old 4 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status score &lt; /=3 5 . The following baseline laboratory data : Serum bilirubin &lt; /=1.5 x upper limit normal ( ULN ) &lt; /= 3 x ULN patient Gilbert 's disease ; Serum creatinine &lt; /=1.5 x ULN AND creatinine clearance &gt; 30 ml/min ; Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; /=3 x ULN 6 . Females childbearing potential must negative serum urine beta human chorionic gonadotrophin ( betahCG ) pregnancy test result within 14 day prior first dose brentuximab vedotin must agree use effective contraception method study 30 day follow last dose study drug . Females non childbearing potential postmenopausal great 1 year bilateral tubal ligation hysterectomy . 7 . Males partner childbearing potential must agree use effective contraceptive method study 30 day follow last dose study drug 8 . Patients legally authorize representative must provide write informed consent . 1 . History another primary invasive malignancy definitively treated remission least 2 year . Patients nonmelanoma skin cancer carcinomas situ eligible regardless time diagnosis ( include concomitant diagnosis ) . 2 . Documented history cerebral vascular event ( stroke transient ischemic attack ) , unstable angina , myocardial infarction , cardiac symptom consistent New York Heart Association Class IIIIV within 6 month prior first dose brentuximab vedotin 3 . Evidence active cerebral/meningeal disease . Patients may history central nervous system ( CNS ) leukemic involvement definitively treat prior therapy evidence active disease time registration . 4 . Previous treatment antiCD30 direct therapy 5 . Patients previous allogeneic stem cell transplant ( SCT ) meet either follow criterion : &lt; 100 day allogeneic SCT , Acute chronic graftversushost disease ( GvHD ) , Receiving immunosuppressive therapy treatment prophylaxis GvHD within last 7 day 6 . Patients uncontrolled active infection ( viral , bacterial , fungal ) eligible . 7 . Known positive hepatitis B surface antigen expression 8 . Known active hepatitis C infection ( positive polymerase chain reaction antiviral therapy hepatitis C within last 6 month ) 9 . Preexisting grade &gt; /=2 peripheral neuropathy 10 . Patients uncontrolled diabetes mellitus 11 . Current therapy systemic antineoplastic antineoplastic investigational agent . 12 . Chemotherapy ( except hydroxyurea emergent use singleagent cytarabine cytoreduction ) , radiotherapy , biologics , and/or treatment immunotherapy complete 2 week prior first dose study drug , unless progressive disease document . NOTE : Hydroxyurea allow first cycle treatment 13 . Females pregnant lactate 14 . Known hypersensitivity excipient contain drug formulation brentuximab vedotin 15 . History progressive multifocal leukoencephalopathy ( PML )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>CD30-Positive</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
	<keyword>Brentuximab Vedotin</keyword>
	<keyword>SGN-35</keyword>
	<keyword>Adcetris</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>Azacitidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>NSC-102816</keyword>
</DOC>